Home / PER.AX : ASX

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does PER.AX make money? Does PER.AX have pricing power? What's the Earnings Whisper? Will PER.AX profit more as the business scales? What is PER.AX's management track record? Is PER.AX's current price justified?

Percheron Therapeutics Limited

AUD 0 -$0.00 (-50.00%)

ASX · 15 Sep 2026 05:45 UTC

Previous Close

AUD 0

Day Range

AUD 0AUD 0

Year Range

AUD 0AUD 0.01

Market Cap

5.01M

AVG Volume

3.65M

Trailing/Forward PE

-1.1/-

PEG ratio

-0

Dividend Yield

Next Earnings Date

2027-02-24

Primary Exchange

Australian Securities Exchange

Net Income (AUD)

PER.AX Net Income (AUD) by quarter
Period	Net Income (AUD)
26 Q4	-1.69M
26 Q2	-3.11M
25 Q4	-6.39M
25 Q2	-8.54M
24 Q4	-7.18M
24 Q2	-4.74M

Operating Income (AUD)

PER.AX Operating Income (AUD) by quarter
Period	Operating Income (AUD)
26 Q4	-2.44M
26 Q2	-3.18M
25 Q4	-8.1M
25 Q2	-8.61M
24 Q4	-8.94M
24 Q2	-5.94M

EBITDA (AUD)

PER.AX EBITDA (AUD) by quarter
Period	EBITDA (AUD)
26 Q4	-2.24M
26 Q2	-3.16M
25 Q4	-7.78M
25 Q2	-8.49M
24 Q4	-8.71M
24 Q2	-5.48M

Cash Flows (AUD)

PER.AX Cash Flows (AUD) by quarter
Period	Cash Flows (AUD)
26 Q4	-2.35M
26 Q2	-2.62M
25 Q4	-7.16M
25 Q2	-8.49M
24 Q4	-5.28M
24 Q2	-4.84M

EPS (AUD)

PER.AX EPS (AUD) by quarter
Period	EPS (AUD)
26 Q4	-0
26 Q2	-0
25 Q4	-0.01
25 Q2	-0.01
24 Q4	-0.01
24 Q2	-0.01

Expenses (AUD)

PER.AX Expenses (AUD) by quarter
Period	Expenses (AUD)
26 Q4	2.24M
26 Q2	3.17M
25 Q4	8.06M
25 Q2	8.58M
24 Q4	8.91M
24 Q2	5.9M

Cash & Debt (AUD)

PER.AX Cash & Debt (AUD) by quarter
Period	Cash & Debt (AUD)
26 Q4	4.05M
26 Q2	4.46M
25 Q4	10.17M
25 Q2	17.39M
24 Q4	11.87M
24 Q2	17.19M
23 Q4	10.97M
22 Q4	19.23M
21 Q4	6.02M
20 Q4	4.06M

Debt ratios

PER.AX Debt ratios by quarter
Period	Debt ratios
26 Q4	0.19
26 Q2	0.16
25 Q4	0.33

Return on Capital

PER.AX Return on Capital by quarter
Period	Return on Capital
26 Q4	-22.39%
26 Q2	-43.51%
25 Q4	-63.84%
25 Q2	-55.82%
24 Q4	-76.64%
24 Q2	-28.84%

Shares Outstanding

PER.AX Shares Outstanding by quarter
Period	Shares Outstanding
26 Q4	1.37B
26 Q2	1.09B
25 Q4	1.02B
25 Q2	931.91M
24 Q4	901.54M
24 Q2	724.11M

Book Value Per Share (AUD)

PER.AX Book Value Per Share (AUD) by quarter
Period	Book Value Per Share (AUD)
26 Q4	0.01
26 Q2	0.01
25 Q4	0.01
25 Q2	0.02
24 Q4	0.01
24 Q2	0.02

Total Assets (AUD)

PER.AX Total Assets (AUD) by quarter
Period	Total Assets (AUD)
26 Q4	8.22M
26 Q2	7.9M
25 Q4	12.44M
25 Q2	17.92M
24 Q4	14.53M
24 Q2	19.98M
23 Q4	12.84M
22 Q4	22.44M
21 Q4	7M
20 Q4	5.35M

Free Cash Flow Yield

PER.AX Free Cash Flow Yield by quarter
Period	Free Cash Flow Yield
Sep 26	-481.14%
Sep 26	-481.14%
Sep 26	-433.03%
Aug 26	-433.03%
Aug 26	-433.03%
Aug 26	-433.03%
Aug 26	-721.71%
Jul 26	-721.71%
Jul 26	-721.71%
Jul 26	-721.71%
Jul 26	-721.71%
Jul 26	-618.61%
Jun 26	-541.29%
Jun 26	-433.03%
Jun 26	-541.29%
Jun 26	-433.03%
May 26	-541.29%
May 26	-541.29%
May 26	-541.29%
May 26	-541.29%
May 26	-433.03%
Apr 26	-433.03%
Apr 26	-541.29%
Apr 26	-433.03%
Apr 26	-433.03%
Mar 26	-419.39%
Mar 26	-457.52%
Mar 26	-503.27%
Mar 26	-369.08%
Feb 26	-369.08%
Feb 26	-359.48%
Feb 26	-314.55%
Feb 26	-314.55%
Jan 26	-279.6%
Jan 26	-314.55%
Jan 26	-314.55%
Jan 26	-279.6%
Jan 26	-279.6%
Dec 25	-314.55%
Dec 25	-314.55%
Dec 25	-251.64%
Dec 25	-359.48%
Nov 25	-359.48%
Nov 25	-314.55%
Nov 25	-359.48%
Nov 25	-359.48%
Oct 25	-314.55%
Oct 25	-314.55%
Oct 25	-279.6%
Oct 25	-251.64%
Oct 25	-228.76%

Price to Book

PER.AX Price to Book by quarter
Period	Price to Book
Sep 26	0.69
Sep 26	0.69
Sep 26	0.76
Aug 26	0.76
Aug 26	0.76
Aug 26	0.76
Aug 26	0.46
Jul 26	0.46
Jul 26	0.46
Jul 26	0.46
Jul 26	0.46
Jul 26	0.53
Jun 26	0.61
Jun 26	0.76
Jun 26	0.61
Jun 26	0.76
May 26	0.61
May 26	0.61
May 26	0.61
May 26	0.61
May 26	0.76
Apr 26	0.76
Apr 26	0.61
Apr 26	0.76
Apr 26	0.76
Mar 26	0.61
Mar 26	0.56
Mar 26	0.51
Mar 26	0.7
Feb 26	0.7
Feb 26	0.72
Feb 26	0.82
Feb 26	0.82
Jan 26	0.92
Jan 26	0.82
Jan 26	0.82
Jan 26	0.92
Jan 26	0.92
Dec 25	0.82
Dec 25	0.82
Dec 25	1.02
Dec 25	0.72
Nov 25	0.72
Nov 25	0.82
Nov 25	0.72
Nov 25	0.72
Oct 25	0.82
Oct 25	0.82
Oct 25	0.92
Oct 25	1.02
Oct 25	1.13
Sep 25	0.61
Sep 25	0.61
Sep 25	0.55
Sep 25	0.55
Aug 25	0.67
Aug 25	0.61
Aug 25	0.58
Aug 25	0.67
Aug 25	0.55
Jul 25	0.55
Jul 25	0.49
Jul 25	0.55
Jul 25	0.49
Jun 25	0.55
Jun 25	0.61
Jun 25	0.61
Jun 25	0.61
May 25	0.67
May 25	0.61
May 25	0.61
May 25	0.61
May 25	0.55
Apr 25	0.61
Apr 25	0.73
Apr 25	0.61
Apr 25	0.67
Mar 25	0.67
Mar 25	1.06
Mar 25	1.06
Mar 25	1.06
Mar 25	0.87
Feb 25	1.25
Feb 25	0.67
Feb 25	0.67
Jan 25	0.77
Jan 25	0.87
Jan 25	0.87
Jan 25	0.87
Jan 25	0.87
Dec 24	0.77
Dec 24	0.67
Dec 24	5.68
Dec 24	6.74
Nov 24	7.13
Nov 24	7.13
Nov 24	7.61
Nov 24	7.7
Nov 24	7.61
Oct 24	7.8

No video analysis for this stock yet. Request one from our team.

News: PER.AX

feeds.newsfilecorp.com · 4 Sep 2026

Edison Issues Report on Percheron Therapeutics (PER)

London, United Kingdom--(Newsfile Corp. - September 4, 2026) - Edison issues report on Percheron Therapeutics (ASX: PER)Percheron's clinical strategy has

proactiveinvestors.com · 31 Aug 2026

Percheron Therapeutics receives $700,000 R&D rebate to support HMBD-002 cancer program

Percheron Therapeutics Ltd (ASX:PER, OTC:PERCF) has received a $700,000 Research and Development Tax Incentive rebate for the 2026 financial year, providing...

proactiveinvestors.com · 5 Aug 2026

Percheron Therapeutics Phase II progress highlighted by Edison with 5.5-cent valuation

Percheron Therapeutics Ltd (ASX:PER, OTC:PERCF) (Percheron Therapeutics Ltd (ASX:PER, OTC:PERCF)) remains on track to begin a Phase II trial of HMBD-002 in...